Skip to main content

Selected Publications


Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.

Journal Article EBioMedicine · June 10, 2024 BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with traditional endocrine therapy (ET) are now the recommended first-line treatment for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (MBC). However, th ... Full text Link to item Cite

Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling.

Journal Article Alzheimers Dement (N Y) · 2024 INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deterioration ... Full text Open Access Link to item Cite

BAYESIAN INFERENCE AND DYNAMIC PREDICTION FOR MULTIVARIATE LONGITUDINAL AND SURVIVAL DATA.

Journal Article Ann Appl Stat · September 2023 Alzheimer's disease (AD) is a complex neurological disorder impairing multiple domains such as cognition and daily functions. To better understand the disease and its progression, many AD research studies collect multiple longitudinal outcomes that are str ... Full text Open Access Link to item Cite

Multivariate functional mixed model with MRI data: An application to Alzheimer's disease.

Journal Article Stat Med · May 10, 2023 Alzheimer's Disease (AD) is the leading cause of dementia and impairment in various domains. Recent AD studies, (ie, Alzheimer's Disease Neuroimaging Initiative (ADNI) study), collect multimodal data, including longitudinal neurological assessments and mag ... Full text Open Access Link to item Cite

Genotypic Effects of the TOMM40'523 Variant and APOE on Longitudinal Cognitive Change over 4 Years: The TOMMORROW Study.

Journal Article J Prev Alzheimers Dis · 2023 BACKGROUND: The 523 poly-T length polymorphism (rs10524523) in TOMM40 has been reported to influence longitudinal cognitive test performance within APOE ε3/3 carriers. The results from prior studies are inconsistent. It is also unclear whether specific APO ... Full text Open Access Link to item Cite

Application of longitudinal item response theory models to modeling Parkinson's disease progression.

Journal Article CPT Pharmacometrics Syst Pharmacol · October 2022 The Movement Disorder Society revised version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts 2 and 3 reflect patient-reported functional impact and clinician-reported severity of motor signs of Parkinson's disease (PD), respectively. Tot ... Full text Open Access Link to item Cite

Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.

Conference Movement disorders : official journal of the Movement Disorder Society · September 2022 BackgroundLongitudinal item response theory (IRT) models previously suggested that the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor examination has two salient domains, tremor and nontremor, that progress in ... Full text Open Access Cite

Bayesian inference and dynamic prediction of multivariate joint model with functional data: An application to Alzheimer's disease.

Journal Article Stat Med · December 30, 2021 Alzheimer's disease (AD) is a severe neurodegenerative disorder impairing multiple domains, for example, cognition and behavior. Assessing the risk of AD progression and initiating timely interventions at early stages are critical to improve the quality of ... Full text Open Access Link to item Cite

Novel Approach to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models.

Journal Article Mov Disord Clin Pract · October 2021 BACKGROUND: Although nontremor and tremor Part 3 Movement Disorder Society-Unified Parkinson's Disease Rating Scale items measure different impairment domains, their distinct progression and drug responsivity remain unstudied longitudinally. The total scor ... Full text Open Access Link to item Cite